IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization

Background Women of Indian ethnicity are underrepresented among randomized controlled trials (RCTs) in reproductive medicine. We compared individualized follitropin delta with conventional follitropin alfa in infertile Indian women undergoing their first ovarian stimulation cycle for (IVF) or intracytoplasmic sperm injection (ICSI). Methods Indian participants, 21–40 years, were recruited from specialist fertility clinics across India to enroll in this assessor-blinded, multicenter bridging trial. Participants were randomly assigned (1:1) to individualized follitropin delta (algorithmic dosing based on serum anti-Müllerian hormone and bodyweight) or conventional follitropin alfa (starting dose 150 IU/day) in a GnRH antagonist protocol. The primary endpoint was the ongoing pregnancy rate per initiated cycle, and treatment difference was adjusted for age stratum (<35, 35–37 and 38–40 years) using the Mantel-Haenszel method. Secondary endpoints included ovarian responses, safety, and tolerability. An exploratory post hoc multivariate logistic analysis for ongoing pregnancy was performed using treatment group, age, AMH subgroup (<15 or ≥15 pmol) and infertility history as covariates. Findings Between 03-Dec-2021, and 13-Dec-2023, 249 participants were screened, 215 randomized, and 213 exposed to the study drug [ n = 99 follitropin delta; n = 114 follitropin alfa; modified intention-to-treat (mITT) analysis set]. Baseline characteristics were mostly similar between groups. The ongoing pregnancy rate was 22.2% (22/99) with follitropin delta vs. 14.9% (17/114) with follitropin alfa (age-adjusted difference 6.9% [95% CI −3.4–17.3]; post hoc multivariate adjusted difference 10.1%; odds ratio 1.99 [95% CI 0.95, 4.19]; p = 0.692). Participants had a mean oocyte yield ± standard deviation of 7.7 ± 5.3 in the follitropin delta group and 6.9 ± 4.2 in the follitropin alfa group. The mean total gonadotropin dose was ∼26% lower with follitropin delta (mean treatment difference −32.0 µg; p < 0.001, post-hoc analysis; mITT). The incidence of adverse events was similar between groups (34.3% vs. 29.8%), with no cases of OHSS reported. Interpretation The IRIS trial demonstrates that individualized dosing of follitropin delta is an effective and safe strategy for ovarian stimulation in Indian women while reducing total gonadotropin dose requirements. Ongoing pregnancy rates were numerically higher with follitropin delta in both the primary analysis and the post hoc multivariate logistic regression analysis, confirming the robustness of the results. Funding Ferring Pharmaceuticals A/S Registration ClinicalTrials.gov: NCT04773353; CTRI: CTRI/2021/04/032835.

Authors

Institutions

Publication Details

Journal
Frontiers in Reproductive Health
Published
2026-11-17
DOI
https://doi.org/10.3389/frph.2026.1916232
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization

Padma Rekha Jirge, Manish Banker, Nayana Patel, Enrica Gravotta et al.
1 links
Frontiers in Reproductive Health
Ovarian function and disorders
article

IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization

Padma Rekha Jirge, Manish Banker, Nayana Patel, Enrica Gravotta, Mirudhubashini Govindarajan, Rita Lobo, Ali Falahati, Neena Malhotra, Sanjeeva Reddy, Shalini Srivastava, Vyjayanthi Srinivasan
article en

Abstract

Background Women of Indian ethnicity are underrepresented among randomized controlled trials (RCTs) in reproductive medicine. We compared individualized follitropin delta with conventional follitropin alfa in infertile Indian women undergoing their first ovarian stimulation cycle for (IVF) or intracytoplasmic sperm injection (ICSI). Methods Indian participants, 21–40 years, were recruited from specialist fertility clinics across India to enroll in this assessor-blinded, multicenter bridging trial. Participants were randomly assigned (1:1) to individualized follitropin delta (algorithmic dosing based on serum anti-Müllerian hormone and bodyweight) or conventional follitropin alfa (starting dose 150 IU/day) in a GnRH antagonist protocol. The primary endpoint was the ongoing pregnancy rate per initiated cycle, and treatment difference was adjusted for age stratum (<35, 35–37 and 38–40 years) using the Mantel-Haenszel method. Secondary endpoints included ovarian responses, safety, and tolerability. An exploratory post hoc multivariate logistic analysis for ongoing pregnancy was performed using treatment group, age, AMH subgroup (<15 or ≥15 pmol) and infertility history as covariates. Findings Between 03-Dec-2021, and 13-Dec-2023, 249 participants were screened, 215 randomized, and 213 exposed to the study drug [ n = 99 follitropin delta; n = 114 follitropin alfa; modified intention-to-treat (mITT) analysis set]. Baseline characteristics were mostly similar between groups. The ongoing pregnancy rate was 22.2% (22/99) with follitropin delta vs. 14.9% (17/114) with follitropin alfa (age-adjusted difference 6.9% [95% CI −3.4–17.3]; post hoc multivariate adjusted difference 10.1%; odds ratio 1.99 [95% CI 0.95, 4.19]; p = 0.692). Participants had a mean oocyte yield ± standard deviation of 7.7 ± 5.3 in the follitropin delta group and 6.9 ± 4.2 in the follitropin alfa group. The mean total gonadotropin dose was ∼26% lower with follitropin delta (mean treatment difference −32.0 µg; p < 0.001, post-hoc analysis; mITT). The incidence of adverse events was similar between groups (34.3% vs. 29.8%), with no cases of OHSS reported. Interpretation The IRIS trial demonstrates that individualized dosing of follitropin delta is an effective and safe strategy for ovarian stimulation in Indian women while reducing total gonadotropin dose requirements. Ongoing pregnancy rates were numerically higher with follitropin delta in both the primary analysis and the post hoc multivariate logistic regression analysis, confirming the robustness of the results. Funding Ferring Pharmaceuticals A/S Registration ClinicalTrials.gov: NCT04773353; CTRI: CTRI/2021/04/032835.

Frontiers in Reproductive HealthVol. 8
Sri Ramachandra Institute of Higher Education and Research (IN), Midas Multispeciality Hospital (IN), Krishna Institute of Medical Sciences (IN), Krishna Maternity and Surgical Nursing Home (IN), Ferring Pharmaceuticals (Denmark) (DK), All India Institute of Medical Sciences (IN)
Good health and well-being
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon